Filter Results

Clinical Studies

Open

  • BD2 Integrated Network Rochester, Minn.

    This research study is designed to fill gaps in our understanding of bipolar disorder. This study involves collecting information from participants to answer key questions relevant to bipolar disorder which might help change or improve the way we do things in the future. This is an observational study and does not involve any additional treatment beyond your standard care at the clinic.

Contact Us for the Latest Status

  • BD2 Integrated Network Scottsdale/Phoenix, Ariz.

    This research study is designed to fill gaps in our understanding of bipolar disorder. This study involves collecting information from participants to answer key questions relevant to bipolar disorder which might help change or improve the way we do things in the future. This is an observational study and does not involve any additional treatment beyond your standard care at the clinic.

Closed for Enrollment

  • Central versus Peripheral Glutamate Biomarkers for Treatment Response during Two Infusions of Intravenous Ketamine for Treatment-Resistant Depression Rochester, Minn.

    This feasibility study aims to better understand the neurobiology of major depression and how ketamine may therapeutically impact brain function. This research may provide important insights into the mechanism of ketamine response, thus, potentially increasing the likelihood of successful treatment interventions and decrease the number of ineffective treatments and/or risk for serious side effects.

  • Long-term Outcomes of a Clinical Ketamine Service for Treatment-resistant Depression Rochester, Minn.

    The purpose of this study is to evaluate and analyze the clinical data that is already being collected for clinical purposes to determine the long-term effects of the repeated use of subanaesthetic ketamine/esketamine for patients with depression.  We hypothesize that patients who have a greater number of infusions/treatments will be more likely to have increased side effects to the drug.  We would like to be able to also analyze data related to any other assessments that are implemented as part of the clinical practice in the future.

     

.